Thread by @KarenMagraith

IMS symposium on CVD at midlife.
First speaker Prof Chrisandra Shufelt (USA).
MHT and CVD: looking back before moving forward.

KEEPS looked transdermal vs oral estrogen, using annual CIMT. No sigt diff.
#IMS2022

ELITE looked at CIMT in groups <6 or >10 yrs post menopause. Increase in CIMT was lower in the early menopause group but not at a level to affect relative risk for CVD. #IMS2022

Women with POI should receive MHT unless contraindicated. #IMS2022

Next speaker. Prof Lisa Larkin (USA)
Migraine management across the lifespan.

CVD and stroke risk inc in patients with migraine with aura. #IMS2022

Early treatment of migraine with triptans increases response and decreases recurrence.

Migraine can worsen at peri menopause and improve after menopause.

Injectable CGRP mAbs are effective.
New agents- oral CGRP ‘gepants’. #IMS2022

Next speaker. Prof Tomi Mikkola (Finland).
History of pre-eclampsia as a CVD risk factor among menopausal women. @IntlMenopause

A history of pre-eclampsia predisposes a woman to approx two fold risk of CVD later in life. #IMS2022

Hormone therapy may prevent IHD and stroke in these patients.

Just an aside. The best academics say ‘I don’t know’ quite frequently during question time.